Skip to content

GlaxoSmithKline Biologicals

Active Public limited companyfounded 1990active for 36 yearsRue de l'Institut 89, 1330 RixensartKBO/BCE: BE 0440.872.918 subsidiary of #1 employer in Belgium, Manufacturing sector

Lifetime

19 annual accounts with figures on one time axis, 35 filings since 1991
peak of €8.86bn in 2023
€7.44bn▼ 5.4%
lowest -€429.6m in 2016
€2.40bn▲ 9.3%
peak of €17.72bn in 2020
€9.98bn▼ 24.9%
€7.24bn▲ 71.8%
peak of 8,968.3 FTE in 2018
8,371 FTE▼ 3.6%
Board13 names since 2018all names
11 directors and 10 others
Owners5 names in the annual accounts
56.64% and 2 others
Documentsfilings and deeds
10-07-202621 days before the deadline
2025financial year
3 directors appointed, 1 resignation 05-112 directors appointed, 8 resignations, 7 reappointments 03-093 directors appointed 30-07Dividend €5.71bnEquity from €13.29bn to €9.98bnDebts from €4.21bn to €7.24bn

Key points

from the 2025 annual accounts

Equity

€9.98bn ▼ 24.9%
13,291.42024+2,396.6Profit-5,711.9Dividend9,976.12025

GlaxoSmithKline Biologicals paid out €5.71bn in dividends. That is 238% of the 2025 profit.

Debts

€7.24bn ▲ 71.8%
Other debts
+3,120.5
Taxes and wages
+5.7
The rest
-102.0

Debts rose by €3.02bn in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Investments

€449.3m 0.3 times depreciation
20212022202320242025

Green is investment, beige is depreciation. Land and buildings stand 11.4% higher than in 2024.

Filings

35 annual accounts 41 filings since 1991
AprilJune31 JulyOctober200020102020

The last five annual accounts were filed 2 to 29 days before the end of the period.

Board

1 joined · 2 left

1 director joined and 2 left, the latest change on 28-07-2026. 11 are in office now.

Position in the sector

€2.40bn

Higher net result than 95% of companies in pharmaceuticals. The sector median is €1.1m, over 61 companies.

Standalone figures, without subsidiaries

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 331 companies had the same profile as GlaxoSmithKline Biologicals has now. Each dot is one company, two years later.

97.6%
were still trading
2.4%
stopped another way
0.0%
went bankrupt
  • Large
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 331 companies, not a prediction for GlaxoSmithKline Biologicals. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director
Daily manager
Director
Director
Director
Auditor,
and 6 others
  • consolidatesannual accounts 2025
  • consolidatedLEI register
  • 22.96%annual accounts 2025
and 1 other shareholder

Shares in 4 companies, including . and

Board & ownership

Recent changes

2 directors appointed, 1 statutory auditor appointed, 2 resignations, 8 reappointments and resign · , and (statutory auditor) appointed · , , , , , and 2 others reappointed · General meeting of 24-06-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0440872918
2 directors appointed, 1 resignation and (mandate holder) appointed · resigns as managing director · Board meeting of 02-04-2026 · Gazette deed
3 directors appointed, 1 resignation resigns as managing director · , (managing director) and (managing director) appointed · Board meeting of 02-09-2025 · Gazette deed
All 86 events

Comparable companies

same main activity, similar in size and age
Company
GlaxoSmithKline Biologicals Rixensart €7,439.8m 35.2% 55.9% 8,371
UCB PHARMA Anderlecht €4,622.6m 7.2% 78.3% 1,960.6
Janssen Pharmaceutica Beerse €21,788.2m 6.8% 54.1% 5,324.5
UCB BIOPHARMA Anderlecht €3,642.1m 3.7% 16.4% 1,395.2
PFIZER MANUFACTURING BELGIUM Puurs-Sint-Amands €1,022.7m 13.9% 76.7% 4,020.8
ZOETIS BELGIUM Ottignies-Louvain-la-Neuve €221.3m 22.7% 88.0% 1,251.7
-10%0%10%20%€50,000€500,000€5m€50m€500m€5bnGlaxoSmithKline BiologicalsEBIT margin

Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.

These companies have the same main activity as GlaxoSmithKline Biologicals: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €2.5bn and €22bn, founded between 1934 and 2013.

Official details

Source: KBO
Status
Active since 01-07-1990Normal situation
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Joint committees
116Chemical industry
207White-collar workers in the chemical industry · annual accounts 2025
Establishment units
2.049.062.0481330 Rixensart, since 31-07-1990
2.151.097.2391300 Wavre, since 01-06-2005and 3 others
Financial year end
31 December
Peppol
Reachable since 06-07-2026
Company details

Annual accounts 2025

€17.83bn▼ 1.5%
Employeeson 31-12-2025
8,504▼ 4.2%
Filing
Filed on 10-07-2026, 31 days before the end of the filing period
Financials

Insights on GlaxoSmithKline Biologicals

GlaxoSmithKline Biologicals has existed since 1990. Turnover grew from €698.4m in 2003 to €7.44bn in 2025 and staff from 1,996.3 to 8,371 full-time equivalents.

Solvency fell in 2025 from 73.4% to 55.9% because of the dividend.

In 2023, three directors stepped down. In November 2025, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about GlaxoSmithKline Biologicals

What is the company number of GlaxoSmithKline Biologicals?
The company number of GlaxoSmithKline Biologicals is 0440.872.918. The VAT number is the same number with BE in front: BE 0440.872.918.
Where is GlaxoSmithKline Biologicals based?
The registered office is at Rue de l'Institut 89, 1330 Rixensart.Company details
What does GlaxoSmithKline Biologicals do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of GlaxoSmithKline Biologicals?
GlaxoSmithKline Biologicals is a public limited company (NV).
When was GlaxoSmithKline Biologicals founded?
GlaxoSmithKline Biologicals was founded on 01-07-1990.
Is GlaxoSmithKline Biologicals still active?
Yes, GlaxoSmithKline Biologicals is an active enterprise in the KBO register.
How many employees does GlaxoSmithKline Biologicals have?
GlaxoSmithKline Biologicals had an average of 8,371 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does GlaxoSmithKline Biologicals fall under?
In its 2025 annual accounts, GlaxoSmithKline Biologicals states joint committees 116 (Chemical industry) and 207 (White-collar workers in the chemical industry).
What is the turnover of GlaxoSmithKline Biologicals?
The turnover of GlaxoSmithKline Biologicals was €7.44bn in financial year 2025, according to the filed annual accounts.
Is GlaxoSmithKline Biologicals profitable?
In financial year 2025, GlaxoSmithKline Biologicals made a profit of €2.40bn.
Where can I find the annual accounts of GlaxoSmithKline Biologicals?
GlaxoSmithKline Biologicals filed 35 annual accounts with the National Bank of Belgium, the latest for financial year 2025. GlaxoSmithKline Biologicals also filed 6 sets of consolidated accounts for the group.
When are the next annual accounts of GlaxoSmithKline Biologicals due?
GlaxoSmithKline Biologicals must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.